Table 1.
Diagnostic and epidemiological data.
| 2014 | 2015 | 2016 | Total | |
|---|---|---|---|---|
| aCDI analyses | 2,613 | 3,196 | 3,526 | 9,335 |
| Toxin test positive (%) | 203 (7.8%) | 235 (7.3%) | 297 (8.4%) | 735 (7.8%) |
| New Cases | 168 | 193 | 228 | 589 |
| Recurrences (%) | 22.0% | 23.3% | 24.6% | 23.3% |
| Age | 67.6 (2–95) | 68.2 (2–98) | 65.7 (2–92) | 67.2 (2–98) |
| Females (%) | 64.3% | 58.5% | 50.4% | 57.7% |
| HO (%) | 93 (55.4) | 104 (53.9) | 110 (48.2) | 307 (52.5) |
| CO-HCFA (%) | 35 (20.8) | 32 (16.6) | 43 (18.9) | 110 (18.8) |
| CA (%) | 35 (20.8) | 49 (25.4) | 63 (27.6) | 147 (24.6) |
| Indeterminate | 5 (3.0) | 8 (4.1) | 12 (5.3) | 25 (4.1) |
| bHO rate | 3.8 | 4.3 | 4.7 | 4.3 |
| cCO-HCFA rate | 1.1 | 1.0 | 1.3 | 1.1 |
| HO average length of stay | 25.2 (2–120) | 21.6 (4–101) | 25.1 (3–116) | 23.9 (2–116) |
| HO days from admission to CDI | 12.3 (2–68) | 10.6 (2–83) | 15.8 (2–99) | 12.9 (2–99) |
| CO-HCFA days from discharge to CDI | 12.9 (3–30) | 15.4 (2–29) | 13.5 (2–30) | 13.9 (2–30) |
aBased on a three step algorithm (i.e., glutamate dehydrogenase-EIA plus toxin-EIA, confirmed by toxin-gene PCR).
bHO as the number of cases per 10,000 patient-days.
cCO-HCFA as the number of cases per 1,000 patient admissions.